ArticleOncogene2023
SOX9 drives KRAS-induced lung adenocarcinoma progression and suppresses anti-tumor immunity.
Open access · greenAbstract read
In one paragraph
Article in Oncogene, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 22 citations in OpenAlex.
- Dipeptidyl peptidase 3 sets the threshold for immune activation and survival during experimental bacterial infection.Nature communications · 2026Article
- Pancreatic organoids and organoid-on-a-chip platforms: from disease modeling to precision therapy.Journal of translational medicine · 2026Review
- ScSpTITH: a rank-correlation framework for robust quantification of multi-dimensional tumor heterogeneity.Human genetics · 2026Article
- A Pan-Cancer Transcriptomic Signature for Conserved Molecular Programs Underlying Premalignant-Malignant Progression Across Common Carcinomas.Dentistry journal · 2026Article
- Spatial single-cell multi-omics characterization of the tumor microenvironment heterogeneity by HER-2 expression status in gastric cancer.Molecular cancer · 2026Article
- Tumor-Associated Neutrophils and Desmoplastic Reaction in the Breast Cancer Tumor Microenvironment: A Comprehensive Review.Cancers · 2026Review
- Serum Aberrant Expression of miR-431-5p and Their Diagnostic Value in Parkinson's Disease.Neurochemical research · 2026Article
- Activating KRAS mutations mark premalignant cystic structures in congenital pulmonary airway malformations.Respiratory research · 2026Article
- A Trojan horse nanoplatform overcoming delivery barriers for targeted gene immunotherapy of colorectal cancer.Frontiers in bioengineering and biotechnology · 2026Article
- Beyond Structure: The Dynamic Role of the Extracellular Matrix Components in Immune Evasion.Cancer communications (London, England) · 2026Review
- Role of the SOX family in non‑small cell lung cancer: Molecular mechanisms and therapeutic implications (Review).Oncology reports · 2026Review
- Mechanical Microenvironment in Tumor Immune Evasion: Bidirectional Regulation Between Matrix Stiffness and Immune Cells and Its Therapeutic Implications.International journal of biological sciences · 2026Review
- Article
- Targeting collagen in "armored and cold" tumors: Overcoming barriers to cancer therapy.Cancer pathogenesis and therapy · 2025Review
- Mechanisms of breast cancer metastasis: the role of extracellular matrix.Molecular and cellular biochemistry · 2025Review
- IRF4 contributes to chemoresistance in IGH::BCL2-positive diffuse large B-cell lymphomas by mediating BCL2-induced SOX9 expression.Clinical and translational medicine · 2025Article
- SOX9: a novel janus-faced regulator in immunity and its promise as a therapeutic target.Frontiers in molecular biosciences · 2025Review
- High expression of SOX10 is correlated with poor prognosis and immune infiltrates in skin cutaneous melanoma.Frontiers in oncology · 2025Article
- High expression of SOX9 is a diagnostic and prognostic indicator of glioma.Frontiers in oncology · 2025Article
- Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development.Trends in cancer · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 2 countries.
Hua ZhongRutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, 08901, USA.ORCID 0000-0002-6534-3376
Wen LuHoward Hughes Medical Institute, Rosalind Russell and Ephraim P. Engleman Rheumatology Research Center, Department of Medicine, Department of Microbiology and Immunology, University of California, San Francisco, CA, 94143-0795, USA.
Yong TangDepartment of Molecular Biology, Princeton University, Princeton, NJ, 08544, USA.
Clotilde WielSahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, University of Gothenburg, 405 30, Gothenburg, Sweden.
Yong WeiDepartment of Molecular Biology, Princeton University, Princeton, NJ, 08544, USA.ORCID 0000-0002-1034-649X
Jian CaoRutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, 08901, USA.
Gregory RiedlingerRutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, 08901, USA.
Thales PapagiannakopoulosPerlmutter NYU Cancer Center, Department of Pathology, New York University School of Medicine, New York, NY, 10016, USA.
Jessie Yanxiang GuoRutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, 08901, USA.
Martin O BergoSahlgrenska Cancer Center, Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 405 30, Gothenburg, Sweden.ORCID 0000-0002-6915-7140
Yibin KangDepartment of Molecular Biology, Princeton University, Princeton, NJ, 08544, USA.ORCID 0000-0002-1626-6730
Shridar GanesanRutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, 08901, USA.
Hatim E SabaawyRutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, 08901, USA.ORCID 0000-0002-7976-303X
Sharon R PineRutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, 08901, USA. sharon.pine@cuanschutz.edu.ORCID 0000-0001-5318-0277
Rutgers, The State University of New Jersey · USPrinceton University · USUniversity of Gothenburg · SEHoward Hughes Medical Institute · USNew York University · US
Funding
Elucidate the mechanism of autophagy in supporting Lkb1-deficient lung tumorigenesis and metastasisR01CA237347 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI GUO, YANXIANG · 2020 to 2025
$1.8MSox9 signaling in lung adenocarcinomaR01CA190578 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI PINE, SHARON R. · 2014 to 2018
$1.7MAmerican Cancer Society (American Cancer Society, Inc.) 134036-RSG-19-165-01-TBGNCI NIH HHS R01 CA190578NCI NIH HHS R01 CA237347U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (OER) R01CA190578U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (OER) R01CA237347U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (OER) R01CA237347-01A1
Abstract
The SOX9 transcription factor ensures proper tissue development and homeostasis and has been implicated in promoting tumor progression. However, the role of SOX9 as a driver of lung adenocarcinoma (LUAD), or any cancer, remains unclear. Using CRISPR/Cas9 and Cre-LoxP gene knockout approaches in the Kras
Indexed as
Adenocarcinoma of LungLung NeoplasmsAnimalsGenes, rasHumansMiceProto-Oncogene Proteins p21(ras)SOX9 Transcription FactorTumor MicroenvironmentKRAS protein, humanProto-Oncogene Proteins p21(ras)SOX9 protein, humanSOX9 Transcription Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.